Product Description
Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Lumefantrine)
Mechanisms of Action: Hematin Inhibitor,Nucleic Acid Synthesis Inhibitor,Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | China | Ecuador | Egypt | France | Greece | India | Indonesia | Ireland | Japan | Malaysia | Netherlands | New Zealand | Pakistan | Peru | Portugal | Slovenia | South Africa | Spain | Sweden | Switzerland | Thailand | Ukraine | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Ministry of Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Burkina Faso, Congo, Gabon, Mali, Thailand, United Kingdom, Unknown Location
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Malaria, Falciparum
Phase 1: HIV Infections|Hepatitis B|Malaria|Pregnancy Outcomes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ALAQ | P1 |
Recruiting |
Pregnancy Outcomes|Hepatitis B|HIV Infections |
2026-08-31 |
|
| KALUMI | P2 |
Completed |
Malaria, Falciparum |
2024-08-13 |
|
| 2023-000804-21 | P3 |
Active, not recruiting |
Malaria, Falciparum |
2023-08-31 |
|
| CKAF156A2107 | P1 |
Completed |
Malaria |
2022-11-22 |
21% |
| CKAF156A2107 | P1 |
Completed |
Malaria |
2022-11-22 |
21% |